MARKET

ONCR

ONCR

Oncorus, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.40
+0.89
+5.74%
After Hours: 15.85 -0.55 -3.35% 18:09 10/26 EDT
OPEN
15.51
PREV CLOSE
15.51
HIGH
16.40
LOW
15.51
VOLUME
67.49K
TURNOVER
--
52 WEEK HIGH
19.30
52 WEEK LOW
14.60
MARKET CAP
358.27M
P/E (TTM)
-8.2416
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 1d ago
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14)
Benzinga · 10/15 12:03
Last Week's Notable Insider Buys: Element Solutions, Selecta Biosciences And More
Insider buying can be an encouraging signal for potential investors when markets face uncertainty. Insiders seemed to be focused on biotech companies last week. Initial public offerings and a SPAC merger encouraged insiders to buy shares.
Benzinga · 10/11 15:35
The Daily Biotech Pulse: Gilead, Lilly COVID-19 Treatment Supply Agreements, CareDx's Positive Preannouncement, Aziyo Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-Week Highs Oct. 7)
Benzinga · 10/08 11:52
Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference
GlobeNewswire · 10/05 21:05
3 Biotech Companies Are Making Their Market Debuts
C4 Therapeutics, Immunome, and Oncorus are the latest to go public.
Barrons.com · 10/02 15:23
Biotechs C4 Therapeutics and Immunome Surge on Their Market Debuts
But Oncorus slumps below its IPO price.
marketwatch.com · 10/02 15:23
Oncorus prices 5.8M-share IPO at $15
Oncorus (ONCR) has priced its IPO of 5.8M common shares at $15.00/share, for expected gross proceeds of ~$87M.Underwriters' over-allotment is an additional 870K shares. Trading kicks off today. Jefferies, Evercore
Seekingalpha · 10/02 10:07
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCR. Analyze the recent business situations of Oncorus, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.51%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
Chairman/Founder/Executive Director
Mitchell Finer
President/Chief Executive Officer
Theodore Ashburn
Chief Financial Officer/Primary Contact
John McCabe
Chief Scientific Officer
Christophe Queva
Vice President
Lorena Lerner
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ONCR
Oncorus, Inc. is a clinical stage biopharmaceutical company focused on developing viral immunotherapies for cancer patients. The Company is leveraging its platforms to develop a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors. The Company is developing a differentiated portfolio of locally and systemically administered oncolytic virus therapies across its oncolytic Herpes Simplex Virus (oHSV) and Synthetic Virus Platform. Its lead product candidates are ONCR-177, ONCR-GBM, Synthetic Coxsackievirus (CV)A21 and Synthetic Seneca Valley Virus (SVV).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Oncorus Inc stock information, including NASDAQ:ONCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCR stock methods without spending real money on the virtual paper trading platform.